NCT07086313 - A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD | Biotech Hunter

Enrollment

315

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions

Attention-Deficit Hyperactivity Disorder(ADHD)

Interventions

DRUG

EB-1020 (Centanafadine) low dose

low dose, capsule, oral, once daily, for 6 weeks

DRUG

EB-1020 (Centanafadine) high dose

high dose, capsule, oral, once daily, for 6 weeks

DRUG

Placebo

Placebo, capsule, oral, once daily, for 6 weeks

Trial Locations (1)

RECRUITING

Hokkaido University Hospital, Sapporo